| | Predictors of Disrupted Social Participation in Myotonic Dystrophy Type 1Abstract Gagnon C, Mathieu J, Jean S, Laberge L, Perron M, Veillette S, Richer L, Noreau L. Predictors of disrupted social participation in myotonic dystrophy type 1. ObjectiveTo identify personal and environmental predictors of the most disrupted participation domains in people with myotonic dystrophy type 1 (DM1). DesignCross-sectional study. SettingOutpatient neuromuscular clinic. ParticipantsAdults (n=200; 121 women), age 18 years or older (mean age, 47y), with a confirmed diagnosis of DM1 were selected from the registry of a neuromuscular clinic (N=416). Fifty-two participants had the mild phenotype and 148 the adult phenotype. InterventionsNot applicable. Main Outcome MeasuresSocial participation in mobility, housing, employment, and recreation was assessed with the Life Habits Measure. Disrupted participation was based on whether help was needed in performing most life habits because of incapacities or environmental barriers. Environmental factors were assessed by using the Measure of the Quality of the Environment. Personal factors were assessed with standardized instruments including the Berg Balance Scale, the Krupp Fatigue Severity Scale, and manual muscle testing. ResultsA large proportion of participants (45%–61%) reported disrupted participation in all 4 domains. Lower-extremity strength (odd ratios [OR], 15.0–5.5; P<.050) and higher fatigue (OR, 6.0–2.6; P<.05) were present in participants with disrupted participation. With regard to environmental factors, family support (OR, 3.6–2.5; P<.05) and public services (OR, 2.8–2.2; P<.05) were perceived as barriers for participants with disrupted participation in most domains. ConclusionsThis study identified personal and environmental factors that may influence the trajectory toward disrupted participation in individuals with DM1. Fatigue, strength, family support, and public services were found to be independent predictors of disrupted participation. List of Abbreviations: CI, confidence interval, CTG, cytosine-thymine-guanine, DM1, myotonic dystrophy type 1, DNA, deoxyribonucleic acid, DCP, Disability Creation Process, EDS, excessive daytime somnolence, ICF, International Classification of Functioning, Disability and Health, LIFE-H, Assessment of Life Habits, MQE, Measure of the Quality of the Environment, OR, odds ratio, QOL, quality of life, SF-36, Medical Outcomes Study 36-Item Short-Form Health Survey, WAIS-R, Wechsler Adult Intelligence Scale−Revised a Neuromuscular Clinic, Centre de réadaptation en déficience physique de Jonquière, Jonquière, QC, Canada b Centre for Interdisciplinary Rehabilitation and Social Integration, Rehabilitation Institute of Québec City, Québec City, QC, Canada c Faculty of Medicine, Université de Montréal, Montréal, QC, Canada d Rehabilitation Department, Faculty of Medicine, Université Laval, Québec City, QC, Canada e Groupe Écobes, Cégep de Jonquière, Jonquière, QC, Canada f Département des sciences de l'éducation et de psychologie, Université du Québec à Chicoutimi, Chicoutimi, QC, Canada g Montréal University Hospital Centre, Montréal, QC, Canada h Département de psychologie, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada. Reprint requests to Cynthia Gagnon, PhD, OT, Cliniques des maladies neuromusculaires, Centre de Santé et de Services Sociaux de Jonquière, 2230 de l'Hôpital, CP 1200, Jonquière, QC G7X 7X2, Canada
Supported by the Neuromuscular Partnership Program of Muscular Dystrophy Canada, the Canadian Institutes of Health Research, and the ECOGENE-21 Project, Coalition to Advance Healthcare Reform (grant no. CAR43283). No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. PII: S0003-9993(08)00213-X doi:10.1016/j.apmr.2007.10.049 © 2008 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved. | |
|